The LILETTA intrauterine device (IUD) is for sale in the United States. The device was launched through partners Medicines360, a San Francisco-based nonprofit pharmaceutical company, and Actavis, a Dublin, Ireland-based pharmaceutical company.
The device, similar in size to Mirena (Bayer Healthcare Pharmaceuticals, Wayne, NJ), was approved by the Food and Drug Administration in February. LILETTA is a flexible, plastic T-shaped system, measuring 32 mm by 32 mm. It releases the progestin levonorgestrel at an initial release rate of 18.6 mcg per day with an average in vivo release rate of about 15.6 mcg per day over three years. The device is labeled for three years of effective use.
The information site (http://bit.ly/1S8SJeM) offers a video on insertion and removal.
The LILETTA intrauterine device is for sale in the United States. The device was launched through partners Medicines360, a San Francisco-based nonprofit pharmaceutical company, and Actavis, a Dublin, Ireland-based pharmaceutical company.
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content